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Abstract 
The important physiological actions of the thyroid hormones are mediated by 
binding to nuclear thyroid hormone receptors (TRs), encoded by two genes TRα 
and TRβ. These receptors act as hormone-dependent transcription factors by 
binding to DNA motifs located in the regulatory regions of target genes and 
recruiting coregulators (coactivators and corepresors), which alter chromatin 
structure. Novel thyromimetics have been developed that bind preferentially 
TRβ and could be used for treatment of hyperlipidemia and obesity. TRβ gene 
mutations cause resistance to thyroid hormones (RTH), characterized by 
unappropriately high thyroid-stimulating hormone (TSH) levels due to lack of 
feedback inhibition of thyroid hormones on the hypothalamus and pituitary 
gland, and to reduced sensitivity of other TRβ target tissues to thyroid 
hormones. Very recently, patients heterozygous for TRα mutations have been 
identified. These patients exhibit clinical symptoms of hypothyroidism in 
TRα target tissues such as intestine or hearth and near normal circulating TSH 
and thyroid hormone levels.  
 
 
 
 
 
 
Thyroid hormone synthesis and metabolism 
The thyroid hormones (THs), triiodothyronine (T3) and thyroxine (T4), play an 
essential role in growth, development, and metabolism. THs are synthetized in 
the follicles of the thyroid gland by iodination of tyrosine residues of the thyroid-
specific protein thyroglobulin (Rubio and Medeiros-Neto 2009). Thyroid 
hormone synthesis is stimulated by the thyroid-stimulating hormone (TSH), 
which is secreted by the thyrotropes of the anterior pituitary gland. In turn, TSH 
release is stimulated by the thyrotropin-releasing hormone (TRH), produced by 
the hypothalamic neurons of the paraventricular nucleus. Under normal 
conditions a feedback mechanism in which circulating thyroid hormones repress 
TSH and TRH gene transcription ensures the production of appropriate 
amounts of thyroid hormones by the thyroid gland. 
THs are released by the thyroid gland to the bloodstream and they enter 
the cells through the ATP-dependent monocarboxylate transporters MCT8 and 
MCT10 and the organic anion transporter proteins (OATPs) (Visser et al. 2011). 
The gene encoding MCT8 is located on the X chromosome, and hemizygous 
MCT8 mutations in males cause the Allan-Herndon-Dudley syndrome, 
characterized by abnormal serum TH levels and severe psychomotor 
retardation (Dumitrescu et al. 2004).  
TH actions are mediated by binding to the nuclear thyroid hormone 
receptors (TRs) (Flamant et al. 2006; Brent 2012). Although the thyroid gland 
produces predominantly T4, T3 is the most active hormone, since it has a 
higher affinity by TRs. The amount of T3 available for binding to the nuclear 
receptors is regulated by the action of selenoenzymes deiodinases (DIOs). 
DIO1 and DIO2 catalyze the conversion of T4 to T3 in target tissues increasing 
intracellular levels of the active hormone, while DIO3 causes hormone 
inactivation since it converts T4 and T3 by inner ring deiodination to the inactive 
metabolites reverse T3 (rT3) and T2, respectively. Mutations in the SECISBP2 
gene, which is required for the synthesis of selenoproteins including TH 
deiodinases, alter the intracellular metabolism of TH and affected patients show 
short stature and delayed bone age (Dumitrescu et al. 2005). 
 
Mechanism of Action of THs 
TRs belong to the superfamily of nuclear receptors and act as ligand-dependent 
transcription factors. Besides TRs, the nuclear receptors superfamily includes 
the receptors for steroid hormones, lipophilic vitamins, cholesterol derivatives, 
and other metabolites, as well as “orphan” receptors with unknown ligands 
(Aranda and Pascual 2001).   
TRs, as well as other non-steroid receptors, even in the absence of 
hormone are preferentially located in the nucleus and can interact directly with 
chromatin (Figure 1). TRs regulate transcription by binding to DNA sequences 
termed positive or negative hormone response elements (TREs), normally 
located in regulatory regions of target genes. The effects of the receptors on 
transcription are mediated through recruitment of coregulators. TRs can bind 
corepressors and actively repress target gene expression in the absence of 
ligand. Upon hormone binding the receptors undergo a conformational change 
that causes corepressor release and the recruitment of coactivator complexes 
and transcriptional activation of genes containing TREs. TRs can also regulate 
expression of genes that do not contain TREs by modulation of the activity of 
signaling pathways and transcription factors that bind to the target promoter, 
and THs can also elicit rapid responses also called “non genomic” or “non-
genotropic” which are not blocked by inhibitors of transcription or translation. 
These rapid actions could be mediated by a fraction of membrane-associated 
nuclear receptors, or by occupancy of a putative membrane receptor coupled 
through appropriate second-messenger systems to the generation of the 
biological response. Through these “non-genomic” mechanisms THs can 
increase intracellular calcium or activate mitogen-activated protein kinases 
(MAPKs) or phosphoinositol-3-kinase (PI3K) to provoke cellular effects (Cheng 
et al. 2010). 
 
The thyroid hormone nuclear receptor isoforms 
TRs are encoded by two genes (α and β). Several TR protein isoforms 
are generated from the primary transcripts of the TRα and TRβ genes (Figure 
2), which are located in human chromosomes 17 and 3, respectively. The α1 
and α2 isoforms are produced by alternative splicing of the TRα gene and differ 
at the carboxy-terminus. Whereas TRα1 is a bona fide receptor, TRα2 cannot 
bind hormone with high affinity and therefore does not function as a receptor, 
having an antagonistic effect on TR actions. By usage of different transcription 
start points the TRβ gene gives rise to two main isoforms β1 and β2, with 
different amino terminus but capable of DNA and hormone binding. Other minor 
TRβ isoform TRβ3, as well as truncated forms with dominant negative activity 
(ΔTRβ3, ΔTRα1 and ΔTRα2) which cannot bind DNA, have been also identified 
in rodents although their functions have not yet been defined (Refetoff and 
Dumitrescu 2007)  
TRα1, TRβ1 and TRβ2 are the main hormone-binding isoforms and 
share a common structure with other nuclear receptor. The relative levels of 
expression of the different TR isoforms vary among cell types and stages of 
development, suggesting that they could have organ-specific functions. Thus, 
TRα1 is more highly expressed in bone, brain, intestine, hearth and skeletal 
muscle, whereas TRβ1 levels are higher in liver and kidney and the expression 
of TRβ2 is restricted to the anterior pituitary, and some neural cells (Lazar 2003; 
Pascual and Aranda 2013). 
The possibility that TR isoforms could mediate specific actions is supported 
by gene inactivation experiments performed in mice. Studies with knockout 
(KO) mice for TRs obtained by homologous recombination have indicated that 
KO mice for α and β TR isoforms have different phenotypes. Deletion of TRα1 
causes reduced body temperature and anomalous heart rate and contractility 
(Wikstrom et al. 1998), whereas TRβ KO mice gene present altered pituitary-
thyroid axis and defects in the inner ear and retinal development (Forrest and 
Vennstrom 2000). Furthermore, in mice lacking both TRα1 and TRα2 postnatal 
development and survival is compromised (Fraichard et al. 1997), while the 
double TRα1/TRβ KO mice, surprisingly, survive indicating that these receptors 
are not essential for viability (Gothe et al. 1999). Furthermore, TRα1/TRβ KO 
mice show bone defects with abnormal growth and a severe dysfunction of the 
pituitary-thyroid axis, which are not present in the single KO mice. TRα1 and 
TRβ can play overlapping functional roles in organs such as the skin, since 
single KO mice present a proliferative defect but not as marked as that found in 
double KO mice (Contreras-Jurado et al. 2011; Garcia-Serrano et al. 2011). All 
these results indicate that TRα1 and TRβ can substitute for each other to 
mediate some actions of the thyroid hormones but they can also mediate 
isoform-specific functions. 
Structure of the thyroid hormone receptors 
TRs and other nuclear receptors exhibit a modular structure with different 
regions corresponding to autonomous functional domains that can be 
interchanged among related receptors without loss of function. A typical nuclear 
receptor consists of a variable N-terminal region (A/B), a conserved DNA-
binding domain (DBD) or region C, a linker region D, and a conserved E region 
that contains the ligand binding domain (LBD) (Figure 2).  
The A/B region is the most variable both in size and sequence and 
contains a ligand-independent transcriptional activation function (AF1). In 
contrast, the DBD is the most conserved domain among nuclear receptors, and 
confers the ability to recognize and bind with high affinity to the TREs. This 
domain comprises two "zinc fingers" and a carboxy terminal extension. In each 
zinc finger, 4 invariable cysteines coordinate tetrahedrically one zinc ion. 
Aminoacids required for discrimination of the TRE are present at the base of the 
first finger in a region termed the "P box", and other residues of the second zinc 
finger that form the so called "D box" are involved in dimerization. Structural 
studies have shown that the core DBD is composed of two α helices. The first 
one, the recognition helix, that binds the major groove of DNA, contains the P 
box that makes contacts with specific DNA bases of the response element. The 
second helix contains the D box and forms a right angle with the recognition 
helix (Rastinejad et al. 1995). 
The D domain is not well conserved among the different receptors and 
serves as a hinge between the DBD and the LBD, allowing rotation of the DBD. 
The D domain in TRs contains residues whose mutation abolishes interaction 
with nuclear receptor corepressors. In addition, this region associates strongly 
with the LBD but only in the presence of ligand or corepressors, exerting a 
stabilizing effect on the overall structure of the receptor (Pissios et al. 2000).  
The LBD is a multifunctional domain that, besides the binding of the 
hormone, mediates homo and heterodimerization and ligand-dependent 
transcriptional activation and repression. The LBDs contains a carboxi-terminal 
AF2 motif responsible for ligand-dependent transcriptional activation. The 
crystal structure of the LBDs shows that are formed by twelve conserved α-
helical regions numbered from H1 to H12. The ligand binding pocket, which 
accommodates the hormone, is mainly made up of non-polar aminoacids and is 
buried within the bottom half of the LBD. The AF2 domain, contained in H12, is 
required for ligand-dependent transactivation. This domain possesses a high 
homology over a very short region that adopts an amphipathic α-helical 
conformation. Although H12 of the LBD contains the core AF2 activity, this 
domain comprises other dispersed elements brought together upon hormone 
binding. One of such elements is a region encompassing the C-terminal half of 
helix 3 and helix 4. Mutations in this region affect neither ligand binding nor 
dimerization, but impair ligand-dependent transactivation. Specifically, a highly 
conserved lysine in the carboxi-terminus of helix 3 is important for 
transcriptional activity not only in TR but also in most receptors (Aranda and 
Pascual 2001).  
Several differences are evident when comparing the unoccupied and 
ligand-bound receptors (Figure 3). The liganded structures are more compact 
than the unliganded ones, demonstrating that upon hormone binding the 
receptors undergo a clear conformational change. The most striking difference 
observed in the receptors upon ligand binding is the position of H12 (Wagner et 
al. 1995). This helix projects away from the body of the LBD in the absence of 
ligand. However, upon hormone binding H12 moves in a "mouse-trap" model 
being tightly packed against H3 or 4 and making direct contacts with the ligand. 
This change generates a hydrophobic cleft responsible for interaction with 
coactivators (Feng et al. 1998).  
 
Dimerization and binding to TREs 
In contrast with steroid receptors that almost exclusively recognize palindromic 
DNA elements, TRs can bind as homodimers or preferentially as heterodimers 
with other nuclear receptor, the retinoid X receptor or RXR, to TREs composed 
of two copies of the AGG/TTCA motif. They are configured as palindromes 
(Pal), inverted palindromes (IPs), or direct repeats separated preferably by 4 
non-conserved base pairs (DR4) (Figure 4). Although TRs can bind to their 
response elements as homodimers, heterodimerization with RXR strongly 
increases the affinity for DNA and transcriptional activity. Therefore, RXR plays 
a dual role in nuclear receptors signaling. On one hand, this receptor binds DNA 
as a homodimer and activates transcription in response to the ligand 9-cis-
retinoic acid, and on the other hand serves as a heterodimeric partner for other 
nuclear receptors, including TRs. Since DRs are inherently asymmetric, 
heterodimeric complexes may bind to them with two distinct polarities. However, 
it has been established that on a DR4 RXR occupies the upstream half-site and 
the heterodimeric partner TR occupies the downstream motif (Kurokawa et al. 
1993). The ability of the TR/RXR heterodimer to bind to palindromes, IPs and 
DR elements implies that the DBDs must be rotationally flexible with respect to 
the LBD dimerization interface and a different region of the DBD of each 
receptor must be used to create the dimerization interface (see Figure 4). Some 
receptor heterodimers can be indistinctly activated by ligands of either RXR or 
its partner receptor, and are synergistically activated in the presence of both 
ligands. In contrast, it was believed that formation of the TR/RXR heterodimer 
precluded binding of ligand to RXR, and that in these complexes RXR would to 
be a “silent partner” with the only function of increasing binding to the TRE. 
However, more recent data indicate that RXR can bind ligand and recruit 
coactivators as a heterodimer with TR, demonstrating that in particular cellular 
environments this receptor can act as a "non-silent" partner of TR, allowing 
stimulation by RXR agonists (Castillo et al. 2004). 
 
Coactivators  
The packing of DNA in nucleosomes provides a major obstacle for gene 
transcription. Two major mechanisms alleviate the block of transcription caused 
by the nucleosomal structure: histones can be post-translationally modified to 
destabilize chromatin, and nucleosomes can be disrupted through the activity of 
ATP-driven machines.  
Histones are subjected to a great variety of post-translational 
modifications, including acetylation, methylation, phosphorylation, ubiquitylation, 
sumoylation, and ADP-ribosylation. These modifications occur in a number of 
residues on the amino-terminal and carboxy-terminal histone “tail” domains, 
which play an essential role in controlling the folding of nucleosomal arrays into 
higher-order structures. Specific histone modifications can be associated to 
transcriptional activation, whereas others are associated with repression. This 
has led to the ‘histone code’ hypothesis (Jenuwein and Allis 2001), in which 
specific combinatorial sets of histone modification signals can dictate 
transcriptional activation or repression. 
Chromatin of transcriptionally active genes has been known for a long 
time to be enriched in hyperacetylated histones. Histone acetylation is catalyzed 
by histone acetyltransferases (HAT), whereas acetyl groups are removed from 
the histone tails by the action of histone deacetylases (HADCs). The receptors 
do not possess HAT enzymatic activity that could modify the histones, but they 
associate with coactivator complexes with HAT activity. A well-known family of 
coactivators that are recruited to TRs and other nuclear receptors in a ligand-
dependent manner is the SRC/p160 family with three related members: SRC-
1/NCoA-1, SRC/2TIF-2/GRIP-1/NCoA-2 and p/CIP/ACTR/AIB1/TRAM1/RAC3. 
Studies performed in genetically modified mice show that despite their similarity 
p160 coactivators show non-redundant actions, since SRC-1 KO mice display 
resistance to TH (RTH) with increased circulating TSH levels despite an 
increase in serum free TH levels, whereas TIF-2 KO mice have normal thyroid 
function (Weiss et al. 1999). In addition, deletion of both SRC-1 and TIF-2 
results in marked increases of serum TH and TSH concentrations, and double 
heterozygous animals show a phenotype of resistance to TH similar to that 
found in SRC-1 KO mice. This indicates a gene dosage effect in nuclear 
coactivators manifesting as haploinsufficiency and functional redundancy of 
SRC-1 and TIF-2 (Weiss et al. 2002). 
p160 coactivators possess HAT activity and act as primary coactivators, 
interacting with TRs and other nuclear receptors, but they also serve as 
platforms for the recruitment of secondary coactivators (York and O'Malley 
2010). The p160 family of coactivators shows a conserved structure, with a 
nuclear receptor-interacting domain (RID) in their central region. The RID 
contains three highly conserved LxxLL motifs, where L is leucine and x is any 
aminoacid, and mediates association of the coactivators to hormone-bound 
receptors. The cocrystal structure of the LBD of TR and a p160 fragment 
containing two LxxLL motifs indicates that the conserved glutamic acid in H12 
and lysine in H3 of the receptor make hydrogen bonds to leucines 1 and 5 of 
the coactivator RID. These contacts form a charge clamp that orients and 
positions the coactivator RID into the hydrophobic groove formed in the LBD 
after the conformational change elicited by ligand binding (Darimont et al. 
1998). This explains why mutation of these residues in TRs renders a 
transcriptionally inactive receptor. Furthermore, mice homozygous for the 
knock-in mutation at E457 in H12 of TRβ, resulting in disruption with p160 
coactivators, have high serum TSH and TH levels, consistent with resistance to 
TH (RTH) and demonstrating that the AF-2 domain is required for up-regulated 
and down-regulated TH action (Ortiga-Carvalho et al. 2005). 
The N-terminal domain of p160 coactivators mediates interactions with 
several transcriptional activators, with BAF57 a component of ATP-dependent 
chromatin remodeling factors, and with a coiled coil coactivator (CoCoA). p160 
coactivators also contain two domains with intrinsic transcriptional activity. The 
stronger transactivation domain (AD1) is the region of interaction with the HAT 
CBP/p300, which serves coactivator roles for many different types of 
transcription factors, acting as cointegrator of extracellular and intracellular 
signaling pathways and is also an essential coactivator for the receptors. p160 
coactivators also associate with PCAF, the first identified mammalian HAT. 
Thus, p160 coactivators might serve as a docking platform to bridge protein 
complexes with HAT activity to the DNA-bound TR. Histone acetylation is a 
critical step in nuclear receptor-mediated hormone signaling and it has been 
shown that in vivo histone acetylation levels of nuclear receptor target genes is 
strongly induced upon treatment with the corresponding ligand.  
Methylation of histones in arginine residues has been also demonstrated 
to be associated to gene activation (Lee and Stallcup 2009). Interestingly, a 
transactivation domain (AD2) located in the carboxi-terminus of p160 
coactivators has been shown to interact with secondary coactivators with 
histone arginine methyltransferase (HMT) activity such as CARM1 (cofactor-
associated arginine methyltransferase 1) and PRMT (protein arginine 
methyltransferase). Their coactivator potential is dependent on an intact histone 
methyltransferase domain, and CARM1, p160 and CBP/p300 act synergistically 
to enhance ligand-dependent transcriptional activation by the receptors (Lee et 
al. 2005). 
Formation of the transcriptional initiation complex in RNA polymerase II 
dependent promoters requires binding of the general transcription factors 
(GTFs). Performed complexes, composed of the RNA polymerase II, GTFs, 
SRBs (supressor of RNA polymerase B) and several other proteins, termed “the 
holoenzyme”, can be directly recruited to the promoter by sequence-specific 
transcription factors. A multiprotein complex denominated TRAP (thyroid 
receptor associated proteins) that interacts with TR (and other nuclear 
receptors) in a ligand-dependent manner and enhances the ligand-dependent 
transcriptional activity has been isolated. This complex is equivalent to the yeast 
Mediator complex that together with SRB proteins associates with the large 
subunit of RNA polymerase. It is believed that the TRAP complex acts by 
recruiting the polymerase holoenzyme to the target promoter. The TRAP 
complex is recruited to the core AF2 TR region in response to hormone binding 
through a single subunit (TRAP220) via a LxxLL motif identical to that found in 
the p160 coactivators (Fondell et al. 1996; Yuan et al. 1998).  
TH-dependent transcriptional activity requires recruitment of both TRAP 
and p160 coactivator complexes to TR. As both coactivator complexes interact 
with the same receptor region they could compete with each other for binding to 
the receptor. Studies employing chromatin immunoprecipitation (ChIP) assays 
have shown that p160 and TRAP coactivator complexes are recruited to 
hormone-regulated promoters in a sequential manner. p160 complexes act 
earlier than TRAP and this ordered recruitment may proceed for multiple cycles 
of factor association and dissociation, with multiple rounds of transcription 
occurring within each cycle (Metivier et al. 2006).  
In summary, binding of hormone to TRs allows the recruitment of 
coactivators with unique biochemical activities at temporally appropriate times 
during the transcription process. The receptors can recruit first coactivators with 
HAT and arginine HMT activity resulting in histone acetylation and methylation. 
Once chromatin has been uncondensed, the receptors via their association with 
the TRAP complex would be able to recruit the transcriptional machinery 
resulting in stimulation of target gene expression (see Figure 5). 
 
 Corepressors  
In addition to hormone-dependent gene activation, in the absence of ligand TRs 
can repress basal transcription of TRE-containing genes. Binding of hormonal 
ligand to the receptor releases the transcriptional silencing and leads to gene 
activation. The current model of gene regulation by these receptors assumes 
that the unliganded receptors are bound to the TRE and that under these 
conditions are associated with corepressors responsible for the silencing 
activity. The best characterized corepressors that associate with TR are 270-
kDa cellular proteins named NCoR (nuclear corepressor) and SMRT (silencing 
mediator for retinoic and thyroid hormone receptors) (Chen and Evans 1995; 
Horlein et al. 1995). In contrast with coactivators, unliganded TRs interact 
strongly with corepressors and THs induce their dissociation from the receptors. 
NCoR and SMRT are related both structurally and functionally. They contain 
three autonomous repressor domains (RD) and a receptor interacting domain 
(RID) located toward the carboxyl terminus. The RID is composed of two motifs 
(or CoRNR boxes), with the consensus sequence Lxx I/H I xxx I/L. When 
compared to the LxxLL motif of the coactivators, the CoRNR motif presents an 
amino-terminal extended helix that appears to be required for effective binding 
of the corepressors to the unliganded receptor (Perissi et al. 1999).  
Although a receptor CoR box, located in H1 of the LBD within the hinge 
region, is essential for interaction of receptors with the corepressors, the 
CoRNR motif does not interacts directly with residues in this region, but docks 
to a hybrophobic groove in the surface of the LBD at H3 and 4. Since this 
surface overlaps with that involved in coactivator interaction, coactivator and 
corepressor binding is mutually exclusive. Indeed, the CoRNR motif binds the 
coactivator groove, preventing the AF2 H12 from assuming the active 
conformation. 
  Ligand binding by itself is not sufficient to induce dissociation of 
corepressors. Rather, it appears that the AF2 region serves to trigger the 
release of corepressors from the receptors. H12 is fully inhibitory for 
corepressor binding to most nuclear receptors, but deletion of this region allows 
corepressor interaction and in vivo repression. In the case of TRs, mutation or 
deletion of the AF2 domain increases interactions with corepressors and 
reduces the release of the corepressors after ligand binding, indicating again 
that H12 is inhibitory for corepressor recruitment (Hu and Lazar 2000; Sanchez-
Martinez et al. 2008). 
Transcriptional repression by the corepressor-bound receptors appears 
to be mediated by the recruitment of histone deacetylases (HDACs) to the 
target gene. Although corepressors were thought to act exclusively through the 
indirect recruitment of HDAC1 or 2 (class I deacetylases), via the adaptor mSin3 
protein, the RD3 has been demonstrated to repress transcription by directly 
interacting with class II deacetylases (HDACs 4, 5 and 7). A repressor complex 
containing the corepressors, HDAC3 and transducin beta-like proteins (TBL1 or 
TBL1R) has been identified and appears to be required for repression by TR 
(Guenther et al. 2001; Yoon et al. 2003). TBL1 protein interacts with histone H3 
and is associated with human sensorineural deafness. In vivo, TBL1 is bridged 
to HDAC3 through SMRT and can potentiate repression by the receptors. 
Furthermore, SNF2H, a component of chromatin remodeling complexes, is 
critical for TR mediated repression, showing that gene repression by the 
receptor involves the targeting of chromatin remodeling factors to the repressed 
gene by the HDAC activity of NCoR (Alenghat et al. 2006). 
In summary, compactation of chromatin structure due to recruitment of 
HDAC complexes by the corepressors is involved in transcriptional silencing by 
the unliganded TRs. The conformational changes elicited in the receptors by TH 
binding would cause the dissociation of corepressors and the recruitment of 
coactivator complexes responsible for transcriptional activation (see Figure 5). 
Although NCoR and SMRT are closely related, studies with KO mice 
suggest that they could mediate non-redundant biological actions. NCoR KO 
mice are embryonic lethal, suggesting the SMRT cannot compensate for the 
functions of NCoR in development and survival (Jepsen et al. 2000). On the 
other hand, knockin mice with mutations in the receptor interaction domain 
(RID) of SMRT and NCoR that abolish interaction with TRs show their 
importance in TR signaling (Astapova et al. 2008; Nofsinger et al. 2008). Liver 
specific expression of the mutant NCoR demonstrates that this corepressor 
plays an important in vivo role in transcriptional repression by the unliganded 
TR and that NCoR also mediates TH sensitivity on positive TR targets. When 
the mutant corepressor is ubiquitously expressed mice have low circulating TH 
levels, without TSH elevation, and markers of TH action in peripheral tissues do 
not indicate hypothyroidism. These results indicate that NCoR mediates TH 
sensitivity in vivo and can alter the central set point of the thyroid axis. 
Interestingly, the mutant NCoR reversed much of the resistance phenotype 
seen in a TRβ RTH mutant mouse model (Fozzatti et al. 2011), indicating that 
constitutive TR interaction with a corepressor is an important mechanism for 
RTH. Furthermore, the use a NCoR knockin mouse in which binding to HDAC3 
is genetically disrupted shows that the interaction of NCoR with this deacetylase 
is also important for the control of both positively- and negatively-regulated 
genes by TH in vivo (You et al. 2010). In addition, NCoR appears to play a role 
in the oncogenic actions of a mutated TRβ in thyroid carcinogenesis in mouse 
(Furuya et al. 2007), and is much more potent than SMRT in the inhibitory 
actions of TRβ on cellular transformation by the ras oncogene (Garcia-Silva et 
al. 2011). Furthermore, NCoR but not SMRT has been implicated in thyroid 
hormone resistance (Yoh et al. 1997). 
  
TH analogs 
Although most residues in the ligand-binding pocket are conserved 
between TRα and TRβ, in the last 10-15 years it has been possible to develop 
isoform-specific ligands. TRβ selective agonists are particularly interesting 
because they have the potential to lower cholesterol and induce weight loss due 
to binding to hepatic TRβ, without having side effects in heart rate that is 
controlled by TRα (Baxter and Webb 2009; Webb 2010; Arsanjani et al. 2011). 
One of the best-characterized selective ligands is the TH analog GC-1 
(Sobetirome), which shows approximately 10-fold higher affinity for TRβ than 
TRα  (Scanlan 2010). Other thyromimetics such as GC24, or KB141 show an 
even higher selectivity. In some cases (KB2115, eprotirome), there is also a 
preferential concentration of the analog in the liver compared with the heart, and 
this also contributes to specificity. Other thyromimetic, MB07811, achieves liver 
specificity by being activated after entering hepatocytes by the action of 
cytochrome P450 to generate the TRβ agonist MB07344 (Erion et al. 2007). 
Thyromimetics have been employed in cultured cells, preclinical models and 
different clinical trials (Baxter and Webb 2009; Tancevski et al. 2011). 
Interestingly, in patients in which a statin was not very effective in lowering 
cholesterol, the combination with eprotirome produced a strong improvement of 
LDL levels (Ladenson et al. 2010), suggesting that TR agonists act by a 
mechanism different than that used by other cholesterol-lowering drugs. Very 
recently, it has been suggested that thyromimetics could be used as 
cholesterol-lowering drug in patients lacking LDL receptors for whom current 
therapies are ineffective. In KO mice lacking these receptors, GC-1 increases 
expression of cholesterol 7-α-monooxygenase, a protein involved in hepatic 
synthesis of bile acids from cholesterol and the amount of bile acids excreted in 
feces, lowering cholesterol (Lin et al. 2012). Although TRβ-specific agonists 
show high promise, further studies should establish the longer-term safety of 
these compounds in patients and their clinical value. 
TRα and cardiac-selective ligands may have therapeutic utility in the area 
of heart disease. CO23 was the first thyromimetic developed showing TRα-
specificity in vitro and in vivo and their derivatives CO24 and CO28 show 
enhanced TRα-specificity. Although their clinical importance has not ben tested, 
in tadpoles CO24 caused metamorphosis with precocious hind and fore leg 
emergence, consistent with enhanced TRα activation (Ocasio and Scanlan 
2008).  
TR-antagonists could hypothetically have clinical use in treating 
hyperthyroidism and the cardiac alterations associated with hyperthyroidism, 
such as ischemia and arrhythmias (Malm et al. 2009). TR antagonists such as 
NH3 have been designed and they induce a different receptor conformation 
than T3 (Figueira et al. 2011), but they are not specific for TRα or TRβ (Malm et 
al. 2009). However, and despite its significant potential usefulness, no TRα-
selective antagonists are yet available and no TR-antagonists have been tested 
in clinical trials.  
 
TR gene mutations 
The syndrome of resistance to thyroid hormones (RTH), first described by 
Refetoff in 1967 (Refetoff et al. 1967), is characterized by a decreased 
sensitivity of tissues to the actions of thyroid hormone. The incidence of RTH is 
low (approximately 1 in 40,000), the syndrome is normally inherited in 
autosomal dominant manner, is present at similar frequency in males and 
females and is predominantly due to heterozygous mutations in TRβ  (Refetoff 
and Dumitrescu 2007). However, in approximately 15% of the more than 1000 
cases reported in the literature, mutations in the TR genes have not been found 
(Reutrakul et al. 2000), and the etiology is still unknown. 
The first mutation identified was a single guanine-cytosine replacement 
in the codon for amino acid 340 resulting in a glycine-arginine substitution in the 
LBD of TRβ (Sakurai et al. 1989). We know now that in most families there are 
single nucleotide substitutions in TRβ causing point mutations, in some cases 
the syndrome is due to nucleotide deletions or insertions producing frameshifts, 
and only very rarely the mutation creates a stop codon. Many families share a 
common mutation and these mutations are concentrated in three clusters rich in 
CpG “hot spots”, present in the hinge domain and the LBD (Figure 6A). As can 
be deduced by the position of these mutations, the resulting receptors display a 
reduced hormone binding affinity or altered association with coactivators and 
corepressors. In many cases the mutant receptors show reduced interaction 
with coactivators or increased association with corepressors that are not 
released in the presence of hormone (Refetoff and Dumitrescu 2007). 
Interestingly, whereas heterozygote patients with a mutant and a normal 
TRβ allele suffer RTH, total deletion of one allele does not cause the syndrome 
(Takeda et al. 1992). This is due to the fact that the presence of the mutant TRβ 
interferes with the action of the native receptor, a phenomenon known as 
“dominant negative effect” (Chatterjee et al. 1991). This explains why RTH due 
to TRβ mutation is inherited in a dominant form while inheritance is recessive in 
individuals with TRβ gene deletion. In addition, homozygous mutation of both 
alleles of the TRβ gene causes a very severe RTH (Ferrara et al. 2012) (Figure 
6B). 
Clinical diagnosis of RTH is based on the finding of high TH levels 
together with elevated TSH. This is explained because TRβ is responsible for 
TH feedback to TRH and TSH. In RTH the feedback is impaired because the 
mutant receptor cannot repress efficiently their expression and as a 
consequence of the inappropriate high levels of TSH the thyroid gland is 
hyperactive and more T4 and T3 are produced (Chiamolera and Wondisford 
2009) (Figure 6C). In some patients the elevated levels of thyroid hormones can 
compensate for the defects in the receptor and they show a normal metabolic 
activity with few clinical symptoms. The most common clinical signs in RTH 
patients include goiter and sinus tachycardia, and with less frequency they can 
have developmental delay, short stature, hearing loss, hyperactivity disorder, 
decreased IQ (but not overt mental retardation), and dyslexia (Refetoff and 
Dumitrescu 2007). However, by still unknown reasons, the clinical 
manifestations of the disorder are very variable even in subjects having the 
same TRβ mutation in the same family. In RTH patients coexist symptoms of 
hypo- and hyperthyroidism. The degree and type of affectation of the different 
tissues can be at least partially explained by the differential expression of TRβ 
and TRα. For instance, the heart is a TRα target organ and the elevated TH 
levels induce tachycardia as in hyperthyroid patients. As a consequence of TH 
binding to TRα in bone, a thyrotoxic skeletal phenotype can be also found in 
RTH. However, the high TSH levels, characteristic of hypothyroidism, reflect the 
dependence of the pituitary thyrotropes on TRβ.  
Several knockin mice models mimicking human TRβ mutations have 
been generated to analyze the molecular mechanisms leading to RTH. The 
TRβPV mouse has a C-terminal 14-amino acid truncation deleting the AF2 
domain (Kaneshige et al. 2000), and the TRβΔ337T mouse harbors a frame-
shift mutation in the LBD that abolishes ligand binding and corepressor release 
(Hashimoto et al. 2001). Heterozygote mice manifest many of the abnormalities 
found in RTH patients, including elevated THs and TSH, neurological 
symptoms, abnormal growth or neurological dysfunction (Cheng et al. 2010). It 
has been shown that in vivo the mutant receptors exert their dominant-negative 
activity by competition with the native TRβ or TRα for binding to the TRE and 
for heterodimerization with RXRs (Hashimoto et al. 2001), leading to repression 
of the T3-positively regulated target genes. In addition, a mutant mouse with the 
R429Q mutation, which has normal ligand binding, but causes RTH in humans 
has been created. This mutation causes selective impairment of TH-mediated 
gene repression, while preserving gene stimulation, suggesting that the affected 
domain, necessary for TR homodimerization and corepressor binding, has a 
critical role in negative gene regulation by TH (Machado et al. 2009).  
Until very recently no human mutations of the TRα gene were identified. 
This led to the hypothesis that either TRα mutations were lethal or that they 
could produce a phenotype different from that caused by TRβ mutation. Trying 
to clarify this point, different TRα knockin mice (TRα1PV, TRα1L400R and 
TRα1R384C), with mutations equivalent to others in TRβ causing RTH were 
generated (Kaneshige et al. 2001; Tinnikov et al. 2002; Liu et al. 2003). It was 
found that heterozygote mice were viable and that these mutations were 
associated with skeletal defects and other abnormalities different from those 
found in the TRβ mutants. Significantly, these animals do not present gross 
differences in the activity of the pituitary-thyroid axis, although T4 and T3 had a 
tendency to be low and high, respectively.  
In 2012 two reports describe the first human patients with heterozygous 
TRα mutations (Bochukova et al. 2012; van Mullem et al. 2012). Both mutations 
E403X and F397fs406X map to the C-terminal domain of the receptor, and the 
single nucleotide change causes a premature stop in E403X and a frame-shift 
stop in F397fs306X (Figure 6D). The truncated receptors do not show ligand-
dependent transactivation and have a strong dominant negative effect, inhibiting 
the activity of the native receptors. Since the mutation deletes H12 of TRα, the 
resulting receptor does not recruit coactivators and displays enhanced 
corepressors recruitment that cannot be released in the presence of hormone. 
In agreement with the findings in the TRα animal models, the pituitary-
thyroid axis is not markedly dysregulated in the patients bearing heterozygous 
TRα mutations, explaining why no TRα mutations were identified before in 
RTH. However, TRα mutant patients present normal TSH levels together with 
subnormal reverse-T3, low-normal T4 and high-normal T3 levels, resulting in a 
low T4/T3 ratio. This has led to the suggestion that a reduced T4/T3 ratio 
together with subnormal reverse-T3 levels may represent a thyroid biochemical 
signature that facilitates future identification of additional cases (Schoenmakers 
et al. 2013).  
The patients with TRα mutations present growth retardation, impaired 
bone ossification, constipation, bradychardia and low blood pressure, impaired 
motor coordination and mild cognitive deficits. These signs are suggestive of 
hypothyroidism, indicating severe resistance to THs in tissues such as bone, 
intestine, heart or brain expressing predominantly TRα. In contrast, tissues such 
as hypothalamus, pituitary or liver expressing predominantly TRβ do not show 
TH resistance, as demonstrated by a normal TSH suppression, reduction of 
cholesterol levels after T4 treatment or elevated levels of sex-hormone binding 
globulin (SHBG) (Bochukova et al. 2012; van Mullem et al. 2012).  
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FIGURE LEGENDS 
 
Figure 1. T4 and T3 enter the cell through transporter proteins. Inside the cells, 
deiodinases (DIO1,2) convert T4, the major form of thyroid hormone in the 
blood, to T3. DIO3 produces rT3 and T2 from T4 and T3, respectively. T3 binds 
in the nucleus to TRs that regulate transcription by associating, generally as 
heterodimers with RXR, to response elements (TREs) located in regulatory 
regions of target genes. Activity is regulated by an exchange of corepressor 
(CoR) and coactivator (CoA) complexes. Both receptors and coregulators are 
targets for phosphorylation by signal transduction pathways stimulated by 
extracellular signals. Binding of hormone to a subpopulation of receptors 
located outside the nuclei can also cause rapid “non-genomic” effects leading to 
stimulation of signaling pathways. T4 can also bind to integrin αVβ3 inducing 
mitogen activated protein kinase (MAPK) activity. 
 
Figure 2. Scheme of the main thyroid hormone receptors isoforms encoded by 
the TRα and TRβ genes, depicting the functional domains. The A/B region 
contains the ligand-independent AF1 transactivation domain. The DNA-binding 
domain (DBD) or region C, is responsible for DNA binding. A linker region D 
connects the DBD to the conserved E/F region that contains the ligand binding 
domain (LBD) as well as the dimerization surface and the ligand-dependent 
AF2 transactivation domain. TRα1 and TRα2 vary in the C-terminal region and 
TRα2 cannot bind hormone. TRβ2 has a longer A/B domain and both isoforms 
can bind the thyroid hormone. 
 
Figure 3. Schematic drawing of the receptor ligand-binding domain (LBD) in the 
absence and presence of hormone. α-helices are numbered from 1 to 12. Note 
the different position of the carboxy-terminal H12 that contains the core AF2 
domain in the absence and presence of hormone that allows the exchange of 
corepressors (CoR) and coactivators (CoA) 
 
Figure 4. TRs can bind as homodimers or as RXR heterodimers and can 
recognize diverse TREs in which the consensus AGGTCA motifs can be 
arranged as palindromes (Pal), inverted palindromes (IP), or direct repeats (DR) 
spaced by 4 non-conserved nucleotides. 
 
Figure 5. In the absence of hormone the receptor heterodimer binds 
corepressors (SMRT/NCoR) that interact with histone deacetylases (HDACs) 
either directly or through their association with Sin3. Histone deacetylation 
causes chromatin compactation and transcriptional repression. Upon thyroid 
hormone binding, the receptors recruit different coactivator complexes. Some 
complexes contain histone acetyltransferases and arginine methyltransferases, 
others have ATP-dependent chromatin remodeling activity, and the TRAP/DRIP 
complex recruits the RNA polymerase II (RNAP II) holoenzyme to the target 
promoter. Recruitment of coactivators causes chromatin decompactation and 
transcriptional stimulation. 
 
Figure 6. A) Scheme of TRβ showing the position of the three “hot spots” where 
mutations in the receptor are found in patients with RTH. B) The mutant 
receptors have dominant negative activity, causing RTH in heterozygote 
patients, no phenotype when only one normal allele is present, a very severe 
RTH when both alleles are absent. C) In RTH due to TRβ mutation, T4 and T3 
levels are high due to a defective feedback inhibition on hypothalamus 
production of TRH and pituitary production of TSH. As a consequence TSH 
levels are high, despite the high levels of circulating thyroid hormones and 
enlargement of the thyroid gland can occur. D) Position of the mutations in TRα 
recently identified in patients. Mutations affect the C-terminus of the receptor 
containing the AF2 domain. 
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